Here are the 10-K annual reports from Catheter Precision, Inc. (VTAK) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VTAK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTAK filings page.
Catheter Precision, Inc. filed an amendment to its annual report mainly to expand disclosures on related-party transactions and director independence. The amendment does not change previously reported financial statements.
Key items include an oral employment arrangement with the CEO’s adult daughter, who serves as non-executive chief operating officer and received $165,000 in cash compensation for 2025 plus multiple option and warrant grants. The company also details several financing and restructuring transactions with entities controlled by Executive Chairman and Chief Executive Officer David A. Jenkins.
On December 31, 2025, the company exchanged royalty rights on its LockeT device held by Mr. Jenkins and FatBoy Capital, LP for 9,489.488 shares of Series J Convertible Preferred Stock, with a $1,000 stated value per share. The exchange eliminated approximately $2.7 million of related-party royalty payables, recognized $5.3 million as additional paid-in capital, and created a $2.6 million loss on debt extinguishment. The Series J Preferred Stock is convertible into 6,083,005 common shares at $1.56 per share if stockholders approve the underlying share issuance.
The company also extended maturity dates on related-party promissory notes totaling $1.5 million and issued 340,000 Series M warrants at a $1.56 exercise price to Mr. Jenkins and FatBoy, valued at about $509,000. Additional disclosures cover the transfer of non-operating PeriKard, LLC membership interests to Mr. Jenkins, formation of majority-owned subsidiaries Cardionomix, Inc. and KardioNav, Inc. with minority stakes granted to Mr. Jenkins and affiliates, and waiver of a 9.99% beneficial ownership limit to allow the Jenkins Family Charitable Institute to exercise 12,368 prefunded warrants. The board also reaffirms that three non-employee directors meet NYSE American independence standards and outlines committee compositions.
Catheter Precision, Inc. outlines its cardiac electrophysiology-focused business built around the VIVO 3D mapping system and LockeT vascular closure device, alongside new subsidiaries Cardionomix and KardioNav targeting heart failure and device-integrated mapping technologies. The company reports a going concern uncertainty, highlighting an accumulated deficit and reliance on external financing after raising approximately $4.9 million in 2025. As of March 20, 2026, it had 2,692,473 shares outstanding and a June 2025 public float valued at about $3.9 million. Management plans to grow by expanding VIVO indications, building clinical evidence for LockeT, leveraging international approvals, and selectively pursuing complementary technologies, but warns of significant regulatory, reimbursement, competition, and capital-raising risks.